---

ACUTE BRONCHIOLITIS

1. Definition

• Age group: 0-24 months (peak: 3-6 months)
• A clinical diagnosis - based on history and physical examination
• CPG note (AAP/CPS): No laboratory or radiological investigations are needed to establish the diagnosis in typical cases.

---

2. Etiology

• Co-infection with multiple viruses occurs in 10-30% of hospitalized children
• Primary RSV infection does NOT confer lifelong immunity; reinfections occur throughout life (milder in older patients)

• Age <12 weeks (especially <6 weeks)
• Prematurity (<35 weeks gestation)
• Bronchopulmonary dysplasia (BPD)
• Hemodynamically significant congenital heart disease
• Immunodeficiency
• Neuromuscular disease
• Cystic fibrosis
• Down syndrome
• Low birth weight

---

3. Pathophysiology

1. Viral entry - RSV (or other virus) infects upper respiratory epithelium, spreads to small airways (bronchioles)
2. Epithelial necrosis - destruction of bronchiolar epithelial cells
3. Inflammation - peribronchial lymphocytic infiltration, submucosa edema
4. Mucus hypersecretion - impaired mucociliary clearance
5. Airway obstruction - partial obstruction leads to ball-valve effect:
   • Air trapping and hyperinflation
   • Complete obstruction leads to atelectasis (absorption collapse)
6. V/Q mismatch - hypoxemia results
7. Increased work of breathing - tachypnea, retractions
8. Feeding difficulty - due to respiratory effort and nasal congestion

In infants, the small caliber of airways means even minimal inflammation causes significant obstruction (resistance is inversely proportional to radius^4).

---

4. Symptoms (History)

• Rhinorrhea (runny nose)
• Sneezing
• Low-grade fever (38-39°C)
• Mild cough

• Worsening cough
• Tachypnea (fast breathing)
• Feeding difficulty (poor oral intake <50-75% of normal)
• Irritability
• Audible wheeze

• Duration and progression of symptoms
• Feeding history (number of feeds, volumes, wet nappies)
• Apneic episodes (especially in very young infants)
• Fever
• Exposure history (sick contacts, daycare)
• Premature birth, comorbidities
• Vaccination history

---

5. Physical Examination Findings

• Tachypnea (most reliable early sign)
• Tachycardia
• Variable degrees of respiratory distress
• Irritability or lethargy (severe)
• Signs of dehydration (sunken fontanelle, dry mucosa, decreased skin turgor)

• Nasal flaring
• Intercostal, subcostal, suprasternal retractions
• Grunting (indicates severe disease)
• Prolonged expiration
• Chest hyperinflation (barrel chest - increased AP diameter)
• On auscultation:
  • Expiratory wheeze (diffuse)
  • Fine end-inspiratory crackles
  • Reduced air entry in severe cases

• Cyanosis
• Silent chest (no wheeze = no air movement)
• Altered consciousness
• Severe subcostal recession

---

6. Clinical Features (Summary)

• First episode of wheeze before age 12 months (key distinguishing feature from asthma)
• Typical course: 2-3 day prodrome → 3-5 days of peak symptoms → gradual resolution over 7-14 days
• Total illness duration: 7-21 days (cough can persist up to 3 weeks)
• Fever is common but not universal
• SpO2 may drop, especially during feeds and sleep
• CXR (if done): hyperinflation, peribronchial cuffing, patchy atelectasis

---

7. Investigations

CPG adds: For febrile infants <28 days with bronchiolitis admitted to hospital, consider UA + urine culture ± blood culture. Serious bacterial infection rate is low but not zero.

---

8. Hospital Admission Criteria

• SpO2 persistently <92% on room air (some guidelines use <90%)
• Moderate to severe respiratory distress (RR >60/min, significant retractions, grunting)
• Apnea (witnessed or reported)
• Unable to maintain adequate hydration (feeding <50% of normal, signs of dehydration)
• Age <6 weeks (or <12 weeks with risk factors)
• High-risk infant (prematurity, CHD, BPD, immunodeficiency)
• Uncertain diagnosis
• Toxic/ill appearance
• Unreliable caregiver or inability to follow up within 24 hours

• Respiratory failure requiring ventilatory support
• SpO2 not correcting despite O2 ± HFNC
• Apnea with desaturation
• Severe impairment of general condition

---

9. Severity Assessment

---

10. Management

Outpatient (mild disease)

• Parental education and anticipatory guidance
• Nasal saline drops + bulb suction (gentle suctioning before feeds)
• Encourage breastfeeding, frequent small feeds
• Maintain hydration (adequate wet nappies)
• Fever: paracetamol/ibuprofen
• Upright/semi-reclined positioning
• Avoid smoke exposure
• Clear indications to return to ED

Inpatient (moderate-severe)

• Salbutamol/albuterol (bronchodilators) - no benefit
• Corticosteroids - no benefit, potential harm
• Antibiotics - unless bacterial superinfection documented
• Antiviral agents (ribavirin) - not routinely
• Chest physiotherapy - no benefit
• Cool mist or saline aerosol

• SpO2 ≥92-94% on room air for 8-12 hours (including during sleep and feeding)
• Adequate oral feeding
• Adequate caregiver support
• Follow-up arranged

---

11. Prevention

---

12. Prognosis

• The vast majority of healthy infants have a self-limiting illness, full recovery in 7-21 days
• Mortality is very low in developed countries (<1% in hospitalized infants), but higher in high-risk groups
• Long-term associations:
  • Increased risk of recurrent wheeze in early childhood (30-40% after RSV bronchiolitis)
  • Possible link to development of asthma (causal vs shared predisposition is debated)
  • Some studies show association with allergic sensitization
• Poor prognostic factors: age <6 weeks, prematurity, congenital heart disease, immunodeficiency, SpO2 <90%

---

---

PNEUMONIA IN CHILDREN

1. Definition and Classification

Classification

• Pneumonia (previously "fast breathing pneumonia"): fast breathing ± chest indrawing → treat with oral amoxicillin at home
• Severe pneumonia: general danger signs (inability to drink/feed, vomiting everything, convulsions, lethargy/unconscious, stridor, hypoxemia) → hospitalize + IV antibiotics

---

2. Pathophysiology

1. Inhalation or aspiration of pathogen into lower respiratory tract
2. Colonization of alveoli - organism overcomes mucociliary clearance and alveolar macrophage defenses
3. Inflammatory response - cytokine release, neutrophil recruitment
4. 4 stages of lobar pneumonia (bacterial):
   • Congestion (day 1-2): hyperemia, serous exudate floods alveoli
   • Red hepatization (day 2-4): RBCs + fibrin + neutrophils fill alveoli, lung solid/red
   • Grey hepatization (day 4-8): RBC lysis, fibrin, macrophages - grey appearance
   • Resolution (day 8+): enzymatic digestion and resorption of exudate, restoration of normal alveolar architecture
5. Resulting V/Q mismatch and shunting → hypoxemia
6. Pleurisy - if inflammation extends to pleura → pleural effusion/empyema

---

3. Aetiology (by age group)

S. pneumoniae remains the most important bacterial pathogen across all childhood age groups. Mycoplasma is the leading cause of atypical/walking pneumonia in school-age children.

---

4. Clinical Approach

A. History

• Cough (productive or dry)
• Fever (usually high-grade in bacterial; low-grade in atypical/viral)
• Fast/difficult breathing
• Chest pain (older children - pleuritic)
• Feeding difficulty / decreased oral intake

• Onset, duration, and progression of symptoms
• Character of cough (wet, dry, barking, paroxysmal)
• Fever - pattern, maximum temperature
• Vaccination history (pneumococcal, Hib, influenza)
• Contact with sick individuals / TB contacts
• Travel history
• Comorbidities (asthma, immunodeficiency, sickle cell, CF)
• Prior episodes of pneumonia
• Antibiotic use prior to presentation
• Chlamydia in neonatal period (maternal STI history - afebrile pneumonia)
• Vomiting / aspiration risk
• Sick day management at home

---

B. Physical Examination

• Temperature (fever - usually >38.5°C in bacterial)
• Work of breathing assessment
• Appearance (toxic vs well-appearing)
• Hydration status
• SpO2 (pulse oximetry - mandatory)
• Capillary refill time

• Abdominal pain/distension (right lower lobe pneumonia can mimic appendicitis)
• Neck stiffness / meningism (meningococcal, pneumococcal)
• Rash (viral exanthems, purpura/petechiae suggesting bacteremia)
• Ear/throat examination

---

C. Tachypnea Thresholds by Age (WHO/PIDS-IDSA)

Tachypnea is the single most sensitive and specific clinical sign for pneumonia in children. It is more reliable than auscultatory findings.

• Neonate (0-1 month): 40-60 bpm
• 1-12 months: 30-60 bpm
• 1-3 years: 24-40 bpm
• 3-6 years: 22-34 bpm
• 6-12 years: 18-30 bpm

• 12 years: 12-20 bpm

---

D. Severity Assessment

• Fever <38.5°C
• Mild increase in RR
• SpO2 >92% in room air
• Normal feeding
• Capillary refill <2 seconds
• Non-toxic appearance

• SpO2 <90% on room air
• Severe respiratory distress / impending respiratory failure
• Toxic/septic appearance
• Altered consciousness
• Unable to feed

---

E. Hospitalisation Criteria

• SpO2 <92% on room air (persistent)
• Severe or very severe respiratory distress (tachypnea, marked retractions, grunting, cyanosis)
• Signs of sepsis / toxic appearance
• Age <3-6 months (especially <1 month)
• Underlying comorbidities (immunodeficiency, sickle cell, CHD, CF)
• Suspected CA-MRSA or other virulent organism
• Complicated pneumonia (effusion, empyema, abscess, necrotizing)
• Unable to maintain oral hydration / vomiting
• Failed outpatient therapy (worsening after 48-72 hrs on antibiotics)
• Concern about observation/compliance at home
• Social circumstances / unable to follow up

• Mechanical ventilation required
• Fluid-refractory septic shock
• Progressively worsening hypoxemia despite O2
• Altered mental status

---

F. Investigations

---

G. Inpatient Management

• Oxygen therapy: target SpO2 ≥94% (≥92% acceptable per some guidelines). Delivery: nasal prongs → face mask → HFNC → CPAP/intubation
• IV fluids: if unable to feed, maintain hydration. Watch for SIADH (restrict to 2/3 maintenance in severe cases)
• Antipyretics: paracetamol 15 mg/kg/dose QID, or ibuprofen 10 mg/kg/dose TID (>3 months)
• Positioning: upright
• Nutritional support: NG feeds if needed
• Monitoring: continuous SpO2, vitals q2-4h, I/O chart

• Duration: typically 5-10 days depending on severity and organism
• Step-down to oral when clinically improving and tolerating feeds
• De-escalate based on culture results

• Diagnostic tap for moderate/large effusions
• Chest tube + fibrinolytics (urokinase) for complex empyema
• Surgical decortication if needed (VATS)

---

H. Outpatient Management

• Antipyretics
• Adequate oral hydration
• Rest
• Avoid smoking exposure
• Return precautions: worsening breathing, cyanosis, inability to feed, lethargy, no improvement after 48 hours

---

Additional Points to Add Per CPG Guidelines

1. Complications of pneumonia (not explicitly in your list but important):
   • Parapneumonic effusion / empyema
   • Lung abscess
   • Necrotizing pneumonia
   • Pneumothorax (especially with S. aureus)
   • Septicemia / bacteremia
   • Meningitis (hematogenous spread)
   • SIADH
2. Prevention of pneumonia (add to your presentation):
   • Pneumococcal conjugate vaccine (PCV13/15) - routine immunization
   • Hib vaccine
   • Influenza vaccine (annual)
   • Measles, pertussis, varicella vaccines
   • Breastfeeding
   • Reduction of indoor air pollution / smoke
   • Nutrition (zinc, vitamin A supplementation in deficient populations)
3. Differential diagnoses (especially for bronchiolitis):
   • Bronchiolitis vs. asthma (first episode vs. recurrent; age; atopic history)
   • Bronchiolitis vs. viral-induced wheeze
   • Pneumonia vs. bronchiolitis
   • Foreign body aspiration
   • Heart failure
   • Pertussis
4. Scoring tools used in some guidelines:
   • Wang Bronchiolitis Severity Score (RR, wheeze, retractions, general condition) - not widely used but may be mentioned
   • PRAM / RDAI (Respiratory Distress Assessment Instrument)
   • PSI/CURB-65 (adults; not validated in children)
5. Nirsevimab (for bronchiolitis) and PCV vaccines (for pneumonia) - latest 2023 updates worth including

---

How to Divide Among 3 Presenters

---

Presenter 1 - "Acute Bronchiolitis: From Pathology to Bedside Assessment"

1. Definition
2. Etiology (viruses, risk factors for severe disease)
3. Pathophysiology
4. Symptoms (history-taking points)
5. Physical examination findings
6. Clinical features
7. Severity assessment (table)

---

Presenter 2 - "Acute Bronchiolitis: Investigations, Management & Prevention"

1. Investigations (and why most are NOT needed - CPG point)
2. Hospital admission criteria
3. Management (outpatient + inpatient)
4. Prevention (hand hygiene, palivizumab, nirsevimab - CPG 2023 update)
5. Prognosis
6. Complications (add this - CPG completeness)
7. Differential diagnosis (brief)

---

Presenter 3 - "Pneumonia in Children: Full Clinical Overview"

1. Definition and classification
2. Pathophysiology
3. Aetiology (by age group)
4. Clinical approach:
   • History
   • Physical examination
   • Tachypnea thresholds by age
   • Severity assessment
   • Hospitalization criteria
   • Investigations
   • Inpatient management
   • Outpatient management
5. Prevention (vaccines - PCV, Hib, influenza)
6. Complications

---

Sources: Canadian Paediatric Society (CPS) Bronchiolitis Statement; AAP Clinical Practice Guideline for Bronchiolitis; Italian Paediatric Society Guidelines 2022 (PMC9912214); PIDS/IDSA CAP Guidelines (PMC7107838); WHO Pneumonia & Diarrhoea Guidelines 2023 (IRIS); Swanson's Family Medicine Review (9780323698115); Fishman's Pulmonary Diseases and Disorders.

---

How Malaysian CPG Compares to What I Gave You

---

ACUTE BRONCHIOLITIS - Malaysian MOH Paediatric Protocols 5th Edition (Chapter 32)

RSV Seasonality in Malaysia (unique to Malaysia)

• RSV is endemic throughout the year in Malaysia (unlike temperate countries where it is strictly seasonal Nov-March)
• However, annual peaks occur in October, November, December, and January
• This is important because Malaysia is tropical - mention this explicitly

High Risk Groups (Malaysian Protocol exact list)

• Age <12 weeks (not <6 weeks as I originally stated - Malaysia uses 12 weeks)
• Premature birth
• Underlying cardiopulmonary disease
• Underlying immunodeficiency
• Underlying neuromuscular disorders

Hospital Admission Criteria - Malaysian Protocol (use this table exactly)

Key difference from AAP/CPS: Malaysia uses SpO2 <95% as the threshold for admission, whereas international guidelines use <90% or <92%. This is more conservative.

Investigations - Malaysian Protocol

• CXR is NOT routinely recommended
• Consider CXR only for:
  • Severe respiratory distress
  • Unusual clinical features
  • Underlying cardiac or chronic respiratory disorder
  • Admission to ICU
• CXR findings: hyperinflation (most common), segmental collapse/consolidation, lobar collapse

Supportive Therapy - Malaysian Protocol

• Nasal suctioning: Do NOT routinely perform upper airway suctioning in all infants. Consider gentle superficial nasal suctioning in younger infants with respiratory distress or feeding difficulties
• HFNC and CPAP/BiPAP are endorsed for moderate-to-severe bronchiolitis requiring non-invasive respiratory support
• Close monitoring on HFNC/CPAP for early detection of progressive respiratory failure requiring mechanical ventilation

Prevention - Malaysian Protocol 2024 update

• Hand hygiene, avoiding sick contacts, avoiding cigarette smoke
• Maternal RSV vaccination at 32-36 weeks gestation is mentioned (Abrysvo - FDA/UK approved, now referenced in Malaysian protocol)
• Palivizumab still mentioned for high-risk groups

Severity Assessment

---

PNEUMONIA - Malaysian Paediatric Protocols (Chapter 34/35 - 4th & 5th Edition)

Definition (Malaysian Protocol - use this exact wording)

1. Bronchopneumonia: A febrile illness with cough, respiratory distress with evidence of localised or generalised patchy infiltrates
2. Lobar pneumonia: Similar to bronchopneumonia except that physical findings and radiographs indicate lobar consolidation

The Malaysian protocol keeps classification simple - just these two clinical-radiological types. No need to overly classify it as WHO/international guidelines do.

Tachypnea Thresholds - Malaysian Protocol (identical to WHO, use these)

Aetiology - Malaysian Protocol (age-based table)

Note: Specific aetiological agents are NOT identified in 40-60% of cases

Severity Assessment - Malaysian Protocol (WHO-based)

Hospitalisation Criteria - Malaysian Protocol (use this list)

• Children aged ≤3 months, whatever the severity
• Fever >38.5°C with refusal to feed and vomiting
• Fast breathing with or without cyanosis
• Associated systemic manifestation
• Failure of previous antibiotic therapy
• Recurrent pneumonia
• Severe underlying disorder (e.g., immunodeficiency)

Key Malaysia difference: age ≤3 months automatically admitted regardless of severity

Antibiotics - Malaysian Protocol

• Consider: clinical + laboratory + radiographic findings + age + local epidemiology + local resistance patterns
• Empiric choices align with age-based pathogens above
• Amoxicillin remains first-line for non-severe CAP (outpatient) per Malaysian/WHO guidelines
• For atypical (school-age, Mycoplasma): macrolides (azithromycin/clarithromycin)

---

What to Add to Your Presentation (Malaysian CPG Gaps)

1. Complications of pneumonia - the Malaysian protocol lists Chapter 35 on Empyema Thoracis separately, implying empyema is a significant local complication worth discussing
2. Local resistance patterns - Malaysian protocol specifically says antibiotic choice should consider local epidemiology and resistance - mention that S. pneumoniae resistance to penicillin exists locally
3. PCV10 → PCV13 transition - Malaysia's NIP changed from PCV10 to PCV13 in 2023 (given at 4, 6, and 15 months). This is a very current Malaysia-specific prevention point for pneumonia
4. RSV endemicity in tropical Malaysia - for bronchiolitis, unlike temperate countries, there is no strict "RSV season" - it circulates year-round with peaks

---

Summary: What Was Previously Correct vs. What Changes for Malaysia

---

Primary source for Malaysia: MOH Malaysia - Paediatric Protocols 5th Edition for Malaysian Hospitals (Chapter 32: Acute Bronchiolitis, Chapter 34: Pneumonia). Also: MPA 4th Edition Paediatric Protocols. Note - there is no standalone dedicated Malaysian MOH CPG on bronchiolitis or paediatric CAP; the Paediatric Protocols book is the primary national reference used in all Malaysian public hospitals.

---

PRESENTER 1

"Acute Bronchiolitis - Background & Clinical Assessment"

1. Definition
   • Viral LRTI, age <2 years, clinical diagnosis
2. Etiology
   • RSV most common; other viruses (hMPV, rhinovirus, adenovirus, parainfluenza, influenza)
   • Co-infections (10-30%)
   • Malaysian context: RSV endemic year-round, peaks Oct-Jan
   • High-risk groups for severe disease (Malaysian protocol: age <12 weeks, prematurity, cardiopulmonary disease, immunodeficiency, neuromuscular disorders)
3. Pathophysiology
   • Viral entry → epithelial necrosis → peribronchial inflammation → mucus hypersecretion → partial/complete airway obstruction → air trapping + atelectasis → V/Q mismatch → hypoxemia
4. Symptoms
   • Prodrome (days 1-3): coryza, low-grade fever, cough
   • Progression (days 3-5): tachypnea, wheeze, feeding difficulty, apnea in young infants
5. Physical Examination Findings
   • Tachypnea, nasal flaring, recessions (inter/subcostal/suprasternal), grunting, hyperinflated chest, expiratory wheeze, crackles on auscultation, central cyanosis (severe)
6. Clinical Features
   • First episode wheeze <12 months
   • Course: 2-3 day prodrome → peak 3-5 days → resolution 7-21 days
   • Apnea in infants <6 weeks without other signs
7. Severity Assessment
   • Mild / Moderate / Severe table (RR, recession, SpO2, feeding, apnea, grunting)
   • Malaysian SpO2 threshold: <95% = concern

---

PRESENTER 2

"Acute Bronchiolitis - Investigations, Management & Prevention"

1. Investigations
   • CXR: NOT routine (Malaysian protocol) - only for severe distress, unusual features, underlying cardiac/respiratory disease, ICU admission
   • CXR findings if done: hyperinflation, segmental/lobar collapse, consolidation
   • SpO2: mandatory
   • Viral panel, FBC, blood cultures: NOT routine
   • Blood gas: only if severe/respiratory failure
2. Hospital Admission Criteria (Malaysian Protocol table)
   • Age <3 months → admit
   • SpO2 <95% → admit
   • Grunting, central cyanosis, moderate/severe recession → admit
   • Apnea, inadequate feeding, toxic-looking, high-risk group → admit
3. Management
   • Outpatient (mild): nasal saline + suctioning, small frequent feeds, paracetamol for fever, parental education, return precautions
   • Inpatient (moderate-severe):
     • Oxygen: target SpO2 ≥95% (Malaysian threshold)
     • Hydration: NG or IV if unable to feed (isotonic fluids, monitor Na for SIADH)
     • Minimal handling
     • Gentle nasal suctioning (not routine - only if distress/feeding difficulty)
     • HFNC/CPAP/BiPAP for moderate-severe (endorsed by Malaysian protocol)
     • Mechanical ventilation if respiratory failure
   • NOT recommended (Malaysian CPG): salbutamol, corticosteroids, antibiotics (unless bacterial superinfection documented), antivirals, chest physiotherapy
4. Prevention
   • Hand hygiene (most effective)
   • Breastfeeding ≥6 months
   • Avoid tobacco smoke and sick contacts
   • Palivizumab: for high-risk groups during RSV season
   • Maternal RSV vaccination at 32-36 weeks gestation (referenced in Malaysian 5th Edition)
   • Hospital: contact + droplet precautions, cohorting
5. Prognosis
   • Self-limiting, majority recover fully in 7-21 days
   • ~1% of children with viral bronchiolitis require hospital admission (Malaysian protocol)
   • Risk of recurrent wheeze and possible asthma link in later childhood

---

PRESENTER 3

"Pneumonia in Children - Full Clinical Overview"

1. Definition & Classification (Malaysian Protocol)
   • Bronchopneumonia: febrile illness + cough + respiratory distress + patchy infiltrates
   • Lobar pneumonia: lobar consolidation on exam and CXR
   • (Brief mention of WHO classification: pneumonia vs severe pneumonia)
2. Pathophysiology
   • Pathogen inhalation/aspiration → alveolar colonization → inflammatory response → 4 stages (congestion → red hepatization → grey hepatization → resolution)
   • V/Q mismatch → hypoxemia; pleural extension → effusion/empyema
3. Aetiology (Malaysian age-based table)
   • Newborns: GBS, E. coli, Klebsiella
   • 1-3 months: Chlamydia trachomatis (afebrile pneumonia)
   • Preschool: S. pneumoniae, H. influenzae b, S. aureus
   • School age: Mycoplasma pneumoniae, Chlamydia pneumoniae
   • All ages: viral (RSV, influenza, adenovirus, parainfluenza)
   • Note: 40-60% cases have no identified organism
4. Clinical Approach:
   A. History
   • Cough, fever (pattern), fast/difficult breathing, feeding, chest pain (older child)
   • Vaccination history, comorbidities, sick contacts, prior antibiotic use, TB contact
   B. Physical Examination
   • SpO2, temperature, tachypnea, nasal flaring, recessions, grunting
   • Dullness to percussion, bronchial breath sounds, crackles, reduced air entry
   • Extrapulmonary: abdominal pain (RLL pneumonia), rash, meningism
   C. Tachypnea by Age (Malaysian/WHO - exact thresholds)
   • <2 months: >60/min
   • 2-12 months: >50/min
   • 12 months-5 years: >40/min

   • 5 years: >20/min

   D. Severity Assessment (Malaysian Protocol)
   • <2 months: Severe (tachypnea + chest indrawing) / Very Severe (not feeding, convulsions, lethargic, fever or hypothermia)
   • 2 months-5 years: Mild (tachypnea only) / Severe (chest indrawing) / Very Severe (not drinking, convulsions, drowsy, malnutrition)
   E. Hospitalisation Criteria (Malaysian Protocol)
   • Age ≤3 months regardless of severity
   • Fever >38.5°C + refusal to feed + vomiting
   • Fast breathing with/without cyanosis
   • Systemic manifestations
   • Failed previous antibiotic therapy
   • Recurrent pneumonia
   • Severe underlying disorder
   F. Investigations
   • SpO2: mandatory
   • CXR: moderate-severe/hospitalized patients
   • FBC, CRP/procalcitonin, blood cultures (hospitalized)
   • NPA/viral panel, pleural fluid if effusion
   • Blood gas if severe
   G. Inpatient Management
   • O2 therapy (target SpO2 ≥94%)
   • IV/NG hydration, antipyretics
   • Antibiotics by age and severity (amoxicillin → ampicillin → ceftriaxone; macrolide for atypical)
   • Empyema: chest tube ± fibrinolytics
   H. Outpatient Management
   • Mild CAP: oral amoxicillin (40-90 mg/kg/day) × 5-7 days
   • Atypical (school-age): azithromycin 10/5 mg/kg × 5 days
   • Supportive care, return precautions, follow-up at 48 hours if not improving
5. Prevention
   • PCV13 in Malaysian NIP since 2023 (at 4, 6, 15 months)
   • Hib vaccine, influenza vaccine, measles, pertussis, varicella
   • Breastfeeding, reduce indoor air pollution, good nutrition

---

Workload Balance Summary

---

PRESENTER 1

"Acute Bronchiolitis - Background & Clinical Assessment"

1. Definition
   • Viral LRTI, age <2 years, clinical diagnosis
   • Most common cause of hospitalization in first year of life
2. Etiology
   • RSV most common (50-80%); hMPV, rhinovirus, adenovirus, parainfluenza, influenza
   • Co-infections occur in 10-30% of hospitalized children
   • Primary RSV infection does NOT confer lifelong immunity
   • Malaysian context: RSV endemic year-round, peaks Oct-Jan
   • High-risk groups (Malaysian Protocol):
     • Age <12 weeks
     • Prematurity
     • Underlying cardiopulmonary disease
     • Immunodeficiency
     • Neuromuscular disorders
3. Pathophysiology
   • Viral entry → bronchiolar epithelial necrosis → peribronchial lymphocytic infiltration + submucosal edema → mucus hypersecretion → impaired mucociliary clearance
   • Partial obstruction → ball-valve effect → air trapping + hyperinflation
   • Complete obstruction → atelectasis
   • V/Q mismatch → hypoxemia
   • Increased work of breathing → tachypnea, retractions
   • Small airway caliber in infants = even minimal inflammation causes significant obstruction
4. Symptoms
   • Prodrome (days 1-3): coryza, low-grade fever, cough, sneezing
   • Progression (days 3-5): worsening cough, tachypnea, wheeze, feeding difficulty, irritability
   • Apnea in very young infants (<6 weeks) may be the only presenting sign
   • Ask about: feeding volumes, wet nappies, apneic episodes, sick contacts, vaccination, comorbidities
5. Physical Examination Findings
   • Tachypnea (most reliable early sign)
   • Nasal flaring
   • Intercostal, subcostal, suprasternal retractions
   • Grunting (indicates severe disease)
   • Hyperinflated chest (barrel-shaped, increased AP diameter)
   • Prolonged expiration
   • Expiratory wheeze (diffuse)
   • Fine end-inspiratory crackles
   • Reduced air entry in severe cases
   • Signs of dehydration
   • Central cyanosis (severe/impending failure)
6. Clinical Features
   • First episode of wheeze before age 12 months
   • 2-3 day prodrome → peak symptoms day 3-5 → resolution 7-21 days
   • Cough can persist up to 3 weeks
   • SpO2 may dip especially during feeds and sleep
   • ~1% of children with viral bronchiolitis require hospital admission (Malaysian Protocol)
7. Severity Assessment (Malaysian/Italian 2022 guidelines)

1. Differential Diagnosis (added)
   • Asthma (recurrent wheeze vs first episode; age; atopic history)
   • Viral-induced wheeze
   • Pneumonia
   • Foreign body aspiration
   • Heart failure
   • Pertussis

---

PRESENTER 2

"Acute Bronchiolitis - Investigations, Management, Prevention & Prognosis"

1. Investigations
   • SpO2 (pulse oximetry): Mandatory in all
   • CXR: NOT routine (Malaysian Protocol). Consider only for:
     • Severe respiratory distress
     • Unusual clinical features
     • Underlying cardiac or chronic respiratory disorder
     • ICU admission
     • CXR findings if done: hyperinflation (most common), segmental/lobar collapse, consolidation
   • Viral panel/RSV swab: Not routine; useful for cohorting/infection control in hospital
   • FBC, blood cultures: Not routine; only if bacterial superinfection suspected
   • Blood gas (ABG/VBG): Only if severe disease or considering ventilation
   • Urine/CSF: Only if sepsis workup needed (febrile infant <28 days)
2. Hospital Admission Criteria (Malaysian MOH Paediatric Protocols 5th Edition - exact table)

• Respiratory failure requiring ventilatory support
• SpO2 not correcting despite O2 ± HFNC
• Apnea with desaturation
• Severe impairment of general condition

1. Management
   Outpatient (mild):
   • Nasal saline drops + gentle bulb suctioning before feeds
   • Small frequent feeds; encourage breastfeeding
   • Paracetamol for fever/discomfort
   • Upright/semi-reclined positioning
   • Parental education and clear return-to-care instructions
   Inpatient (moderate-severe):
   • Oxygen: target SpO2 ≥95% (Malaysian threshold); nasal prongs/face mask
   • Hydration: NG or IV (isotonic fluids - 0.9% NaCl/5% dextrose); monitor serum Na (SIADH risk)
   • Minimal handling
   • Gentle nasal suctioning only if distress or feeding difficulty (not routine)
   • HFNC/CPAP/BiPAP: endorsed by Malaysian Protocol for moderate-severe
   • Mechanical ventilation for respiratory failure
   • Continuous SpO2 monitoring
   NOT recommended (Malaysian CPG and AAP):
   • Salbutamol/bronchodilators
   • Corticosteroids
   • Antibiotics (unless documented bacterial superinfection)
   • Antivirals (ribavirin not routine)
   • Chest physiotherapy
   • Nebulized hypertonic saline (evidence equivocal)
2. Prevention
   • Hand hygiene - most effective non-pharmacological measure
   • Breastfeeding for at least 6 months
   • Avoid tobacco smoke and sick contacts
   • Hospital: contact + droplet precautions, cohorting of RSV patients
   • Palivizumab: monthly IM injection during RSV season for high-risk infants (preterm <29 weeks, hemodynamically significant CHD, BPD)
   • Maternal RSV vaccination at 32-36 weeks gestation - referenced in Malaysian 5th Edition Protocol
   • Nirsevimab (Beyfortus): new long-acting RSV monoclonal antibody, single dose, for all infants entering first RSV season (ACIP 2023) - mention as emerging prevention
3. Prognosis
   • Self-limiting; full recovery in 7-21 days in most healthy infants
   • Low mortality in developed countries (<1% of hospitalized infants)
   • Higher risk in premature, CHD, immunodeficient infants
   • Long-term: 30-40% develop recurrent wheeze in early childhood
   • Possible link to later asthma development (causal relationship still debated)
4. Complications (added)
   • Respiratory failure
   • Apnea and bradycardia
   • Secondary bacterial pneumonia (superinfection)
   • Dehydration
   • SIADH
   • Post-bronchiolitis recurrent wheeze
   • Rare: Bronchiolitis obliterans (especially adenovirus)

---

PRESENTER 3

"Pneumonia in Children - Full Clinical Overview"

1. Definition & Classification (Malaysian Protocol)
   • Bronchopneumonia: febrile illness + cough + respiratory distress + localised/generalised patchy infiltrates
   • Lobar pneumonia: same as above but physical signs and CXR show lobar consolidation
   • WHO severity classification: Pneumonia (fast breathing ± chest indrawing) vs Severe pneumonia (general danger signs)
   • Other classification: Community-acquired vs Hospital-acquired vs Aspiration vs VAP
2. Pathophysiology
   • Inhalation/aspiration of pathogen → overcomes mucociliary and macrophage defenses → alveolar colonization → cytokine release + neutrophil recruitment
   • 4 stages of lobar (bacterial) pneumonia:
     • Congestion (day 1-2): hyperemia, serous exudate
     • Red hepatization (day 2-4): RBCs + fibrin + neutrophils, lung solid/red
     • Grey hepatization (day 4-8): RBC lysis, fibrin + macrophages, grey appearance
     • Resolution (day 8+): enzymatic digestion, resorption, restoration
   • V/Q mismatch + shunting → hypoxemia
   • Pleural extension → effusion/empyema
3. Aetiology (Malaysian Protocol - age-based)

• 40-60% of cases: no organism identified
• Difficult to distinguish viral from bacterial clinically

1. Clinical Approach
   A. History
   • Cough (character: wet, dry, paroxysmal), fever (pattern, degree), fast/difficult breathing
   • Feeding difficulty, chest pain (older children - pleuritic), vomiting
   • Vaccination history (PCV13, Hib, influenza)
   • Comorbidities, sick contacts, TB contact, prior antibiotics, travel history
   B. Physical Examination
   • SpO2 (mandatory), temperature, capillary refill time, general appearance (toxic vs well)
   • Respiratory: tachypnea, nasal flaring, retractions, grunting, head bobbing (infants)
   • Dullness to percussion (consolidation/effusion)
   • Bronchial breath sounds (consolidation)
   • Crackles/crepitations (most common finding)
   • Reduced breath sounds (effusion/collapse)
   • Pleural rub (pleuritis)
   • Extrapulmonary: abdominal pain (right lower lobe pneumonia mimics appendicitis), rash, meningism
   C. Tachypnea Thresholds by Age (Malaysian Protocol/WHO - exact figures)

   Age	Tachypnea (breaths/min)
   <2 months	>60
   2-12 months	>50
   12 months - 5 years	>40
   >5 years	>20

   • Tachypnea = single most sensitive and specific clinical sign of pneumonia in children
   D. Severity Assessment (Malaysian Protocol)
   Age <2 months:
   • Severe: tachypnea + severe chest indrawing
   • Very Severe: not feeding, convulsions, abnormally sleepy/difficult to wake, fever OR hypothermia
   Age 2 months - 5 years:
   • Mild: tachypnea only
   • Severe: chest indrawing
   • Very Severe: not able to drink, convulsions, drowsiness, malnutrition
   E. Hospitalisation Criteria (Malaysian Protocol)
   • Age ≤3 months, whatever the severity
   • Fever >38.5°C + refusal to feed + vomiting
   • Fast breathing with or without cyanosis
   • Associated systemic manifestations
   • Failure of previous antibiotic therapy
   • Recurrent pneumonia
   • Severe underlying disorder (e.g., immunodeficiency)
   F. Investigations
   • SpO2: mandatory
   • CXR: moderate-severe/hospitalized; shows consolidation, infiltrates, effusion
   • FBC + differential, CRP/procalcitonin
   • Blood cultures (hospitalized, moderate-severe)
   • NPA/multiplex PCR viral panel
   • Pleural fluid analysis if effusion present
   • Blood gas if severe hypoxemia
   • Serum electrolytes (SIADH risk)
   • Mycoplasma serology/cold agglutinins (school-age, atypical presentation)
   G. Inpatient Management
   • O2 therapy: target SpO2 ≥94%; nasal prongs → face mask → HFNC → CPAP → intubation
   • IV/NG hydration; monitor for SIADH (restrict to 2/3 maintenance in severe cases)
   • Antipyretics: paracetamol 15 mg/kg/dose QID
   • Continuous SpO2 monitoring, vitals q2-4h, I/O chart
   • Antibiotics (empiric, age-based):

   Age/Severity	First Line	Alternative
   <1 month	IV ampicillin + IV gentamicin	IV cefotaxime
   1-3 months	IV ampicillin + IV gentamicin
   3 months-5 years (moderate)	IV amoxicillin/ampicillin	IV cefuroxime
   3 months-5 years (severe)	IV ceftriaxone 50-100 mg/kg/day	IV ampicillin-sulbactam
   >5 years (atypical)	Azithromycin IV/oral	Clarithromycin
   CA-MRSA suspected	IV clindamycin or vancomycin

   • Complicated empyema: chest tube + fibrinolytics (urokinase); VATS if needed
   H. Outpatient Management
   • Mild CAP, SpO2 >92%, tolerating feeds, reliable carer
   • Oral amoxicillin 40-90 mg/kg/day in 2-3 divided doses × 5-7 days (first line, all ages)
   • Atypical (school-age): azithromycin 10 mg/kg day 1 → 5 mg/kg days 2-5
   • Penicillin allergy: azithromycin or clarithromycin
   • Antipyretics, oral hydration, rest
   • Return precautions: no improvement after 48 hours, worsening breathing, cyanosis, lethargy
   • WHO 2023 update: 3-day amoxicillin acceptable for non-severe fast-breathing pneumonia
2. Prevention (added)
   • PCV13 in Malaysian NIP since 2023 (doses at 4, 6, 15 months)
   • Hib vaccine, annual influenza vaccine, measles, pertussis, varicella vaccines
   • Breastfeeding
   • Reduce indoor air pollution and smoke exposure
   • Good nutrition (zinc/vitamin A in deficient populations)
   • Handwashing
3. Complications (added)
   • Parapneumonic effusion / empyema (significant enough that Malaysian Protocol dedicates a separate chapter - Chapter 35)
   • Lung abscess
   • Necrotizing pneumonia (especially S. aureus)
   • Pneumothorax
   • Bacteremia/septicemia
   • Meningitis (hematogenous spread)
   • SIADH

---

Workload Summary